Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2

Interventions

liposomal amphotericin B 2hypericin 2Vorinostat 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Levofloxacin 2Early Intervention, Educational 2Darbepoetin alfa 2Brentuximab Vedotin 2zanolimumab 1mogamulizumab 1ferrous sulfate 1ferric gluconate 1Vancomycin 1Valacyclovir 1Therapeutics 1Tazobactam 1Sucrose 1Ribavirin 1Radiotherapy 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Phototherapy 1Pharmacogenomic Testing 1Palivizumab 1Ondansetron 1Moxifloxacin 1Morphine 1Methotrexate 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell, Cutaneous × hypericin × Clear all
NCT06470451 2026-04-03

FLASH2

Soligenix

Phase 3 Recruiting
80 enrolled
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT02448381 2022-04-15

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Soligenix

Phase 3 Completed
169 enrolled 13 charts
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡